Answers are grounded in this paper and cite their sources.
Imeglimin is a metformin-derived antidiabetic drug that improves glycemia by optimizing mitochondrial function. Evidence suggests it enhances mitochondrial efficiency and preserves pancreatic β-cell mass (BCM) under diabetic stress. However, its protective effect against hypoxia-induced islet damage, a key cause of early β-cell loss after transplantation, remains unclear. We investigated the effect of imeglimin on hypoxia-induced mitochondrial dysfunction in islets and assessed its impact on an intramuscular islet transplantation model. Under 5% O2, imeglimin preserved mitochondrial membrane potential and normalized reactive oxygen species (ROS) levels, whereas metformin alone failed to reduce ROS. Combined treatment showed complementary mitochondrial protection. Transcriptomic analysis identified restoration of Cox6a2 and attenuation of hypoxia-associated YAP/TAZ target gene signature. In vivo, imeglimin recipients showed improved glycemic control and glucose tolerance, and indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography confirmed greater graft BCM on day 14. Early graft histology revealed reduced apoptosis, oxidative stress marker presence, and HIF1A accumulation, alongside preserved TOMM20 and COX6A2 expression in the imeglimin group. Imeglimin protected pancreatic islets from hypoxia-associated mitochondrial dysfunction, in association with restoration of Cox6a2 expression, and improved early outcomes of intramuscular islet transplantation. These findings support imeglimin as a potential adjunct therapy to preserve islet grafts during the early hypoxic phase after transplantation. ARTICLE HIGHLIGHTS: Imeglimin improves mitochondrial function and preserves β-cells, but its ability to counter hypoxia-induced mitochondrial dysfunction, a key cause of early islet graft loss, has not been established. Under hypoxic conditions, imeglimin preserved mitochondrial membrane potential while suppressing reactive oxygen species (ROS) production and mitophagy; in contrast, metformin did not reduce ROS, indicating a distinct mitochondrial stress-response profile. Transcriptomics implicate restoration of Cox6a2 expression and attenuation of hypoxia-associated YAP/TAZ target gene signatures as potential mechanisms underlying mitochondrial protection. In vivo, short-term imeglimin administration improved glycemic control and preserved graft β-cell mass, as assessed by indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography imaging, accompanied by reduced apoptosis and oxidative stress within graft tissue.
No takes yet. Share an insight, caveat, or question.
Fauzi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: